Source 1primary paper2024MED
Toolkit/adapter CAR (AdCAR) system
adapter CAR (AdCAR) system
Also known as: AdCAR
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
In this review, we summarize the main approaches that have been developed to face such bottlenecks, including the adapter CAR (AdCAR) system...
Usefulness & Problems
No literature-backed usefulness or problem-fit explainer has been materialized for this record yet.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A composed arrangement of multiple parts that instantiates one or more mechanisms.
Mechanisms
No mechanism tags yet.
Techniques
Selection / EnrichmentTarget processes
editingselectionsignalingValidation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
The review summarizes adapter CAR systems, Boolean-logic gating, epitope editing, modulation of cell-intrinsic signaling pathways, safety switches, and co-stimulatory domain selection as main approaches to address CAR-T bottlenecks.
Antigen escape variants, off-tumor destruction of healthy tissues expressing tumor-associated antigens, poor CAR-T cell persistence, and functional exhaustion are prominent hurdles limiting long-lasting remissions with tolerable adverse effects.
CAR-engineered T-cell therapy has achieved unprecedented response rates in some hematological malignancies but remains far from fulfilling its potential, especially in solid cancers.
Approval Evidence
1 source3 linked approval claimsfirst-pass slug adapter-car-adcar-system
In this review, we summarize the main approaches that have been developed to face such bottlenecks, including the adapter CAR (AdCAR) system...
Source:
approach summarysupports
The review summarizes adapter CAR systems, Boolean-logic gating, epitope editing, modulation of cell-intrinsic signaling pathways, safety switches, and co-stimulatory domain selection as main approaches to address CAR-T bottlenecks.
Source:
problem statementsupports
Antigen escape variants, off-tumor destruction of healthy tissues expressing tumor-associated antigens, poor CAR-T cell persistence, and functional exhaustion are prominent hurdles limiting long-lasting remissions with tolerable adverse effects.
Source:
problem statementsupports
CAR-engineered T-cell therapy has achieved unprecedented response rates in some hematological malignancies but remains far from fulfilling its potential, especially in solid cancers.
Source:
Comparisons
No literature-backed comparison notes have been materialized for this record yet.
Ranked Citations
- 1.